PRLog - Feb. 25, 2014 - HYDERABAD, India -- Pharmaceutical drugs, by default, have started incorporating higher concentrations of omega-3 and it is anticipated that, over the coming few years, several new companies would be jumping on to the bandwagon of omega-3 drugs. Several drugs are in Phase II or Phase III clinical trials, with several more expected to come on-stream quite soon. However, the coming year or two is likely to witness an influx of new companies invading the global omega-3 market, provided they obtain the USFDA’s or other relevant authorities’
Omega- 3- Cover- 350X500
In a global scenario where increasing attention is being directed towards issues of sustainability and limited food supplies, algal sources offer immense scope for the rapidly expanding omega-3 market to continue in the same vein. The focus on obtaining EPA and DHA from algae was prompted by an endeavor to seek out more sustainable sources, since EPA and DHA are naturally contained in algae. Moreover, the omega-3 content in fish and krill originates from their consuming the algae directly or other creatures that feed on algae. In addition to being sustainable, algae also allows for farming that can be of help in putting up desirable labels, such as “vegetarian,”
The past several decades have been witness to research studies that have underscored the significance of omega-3 fatty acids in maintaining heart health, in addition to safeguarding against cancer and birth defects and offsetting symptoms of diabetes, arthritis, cognitive decline, depression and several other conditions. Omega-3 Polyunsaturated Fatty Acids (PUFAs) have been growing and continues to grow significantly in the future, attributed to the above benefits.
The report reviews, analyses and projects the market of marine and algal omega-3 polyunsaturated fatty acid ingredients for global and the regional markets including North America, Europe, Asia-Pacific and Rest of World. The regional markets further analyzed for 13 independent countries across North America – The United States and Canada; Europe – Germany, France, Italy, Spain, Norway, Denmark, The United Kingdom and Rest of Europe; Asia-Pacific – China, Japan, South Korea, India and Rest of Asia-Pacific.
Omega-3 Polyunsaturated Fatty Acid (PUFAs) ingredients market analyzed in this study include EPA and DHA omega-3s from marine oils such as fish oils, krill oils and squid oils; and algal oils. The end use application markets covered in the report include dietary supplements, food & beverages, pet nutrition, infant nutrition, pharmaceuticals and clinical nutrition. Worldwide, consumption of Omega-3 polyunsaturated fatty acids (PUFAs), estimated at 123.8 thousand metric tons worth US$2.3 billion in 2013, is forecast to be 134.7 thousand metric tons valued at US$2.5 billion in 2014. By 2020, it is projected that demand for Omega-3 PUFAs globally would reach 241 thousand metric tons with a value of US$4.96 billion, thereby posting a volume CAGR of almost 10% and a value CAGR of 11.6% between 2013 and 2020.
This 410 page global market report includes 126 charts (includes a data table and graphical representation for each chart), supported with meaningful and easy to understand graphical presentation, of market numbers. The statistical tables represent the data for the global omega-3 ingredients market volume in metric tons and value in US$ by geographic region, the product segment and application area. This study profiles 42 key global players and 106 major players across North America – 29; Europe – 35; Asia-Pacific – 30 and Rest of World – 12. The report also provides the listing of the companies engaged in the manufacturing and supply of omega-3 PUFAs as well as major players in the omega-3 end-use industries such as human nutrition, pet nutrition and pharmaceuticals and major ingredient distributors across the globe. The global list of companies covers addresses, contact numbers and the website addresses of 294 companies.
For more details, please visit http://industry-